

S 100–A New Biomarker in Asthma?

Theocharis G Konstantinidis^{1,2*} and Dimitrios Cassimos³

¹Regional Public Health Laboratory, Hellenic CDC, Greece

²Laboratory of Molecular Hematology, Medical School, Democritus University of Thrace, Greece

³Paediatric Department, Medical School, Democritus University of Thrace, Greece

*Corresponding author: Theocharis G Konstantinidis, Laboratory of Molecular Hematology, Medical School, Democritus University of Thrace, Greece; E-mail: tkonsta@med.duth.gr

Received date: Nov 26, 2014, Accepted date: Nov 26, 2014, Published date: Dec 03, 2014

Copyright: © 2014 Konstantinidis TG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Asthma is a chronic inflammatory disease characterized by reversible airway obstruction, airway hyperresponsiveness, and chronic inflammation [1]. The prevalence of asthma varies a lot and unfortunately, has been increasing the last 2 decades. The Global Initiative for Asthma (GINA) estimates that the prevalence of asthma in different countries varies from 1% to 18%. Factors that may trigger or worsen asthma symptomatology are infectious due to viruses, Chlamydia, Mycoplasma or bacteria, exposure to domestic or occupational allergens (e.g., house dust mite, pollens), tobacco smoke environmental factors, exercise or stress [2,3]. It is also known that some drugs can induce asthma, e.g., beta-blockers, antibiotics aspirin or other NSAIDs [4].

S100 and asthma

S100 family proteins are Ca²⁺-binding proteins involved in the regulation of a variety of cellular activities. Patients with chronic inflammation such as rheumatoid arthritis, inflammatory bowel disease and vascular disease have elevated serum levels of S100 proteins [5]. Previous studies have shown that asthmatics had also raised S100 proteins identified in sputum and serum [6,7]. Additionally, S100 proteins are some of the most abundant proteins found in the Bronchoalveolar Lavage Fluid (BALF) of patients with asthma, Chronic Lung Disease (CLD), Chronic Obstructive Pulmonary Disease (COPD), and Acute Respiratory Distress Syndrome (ARDS). Furthermore, Lorenz E., et al found that patients with acute and CLD had significantly higher levels of S100 (S100A8/A9 and S100A12), in comparison to healthy controls [8].

In a previous study we have also shown that anti S100 antibodies were inversely associated with asthma [9]. A possible explanation is that a-Abs cannot be detected because they form complexes with antigens which are in excess in patients with asthma. The production and serum level of a-Abs is regulated by a feed-back mechanism in relation to the level of the relevant auto antigens [10].

S100-dependent mechanisms are involvement in chronic inflammation, cell activation, hyper responsiveness, and airway obstruction (Figure 1). It is well known that the ability of the smooth muscle to contract is fundamental in airway narrowing. S100 protein signaling induces bronchial obstruction by stimulation of smooth muscles [11]. S100 proteins are highly expressed endogenously in neutrophils wherein S100A8/9 composes up to 40% of the cytosolic proteins. S100 secretion by activated neutrophils provokes mast cells

(MCs) activation. Arumugam, et al. reported that sodium cromolyn and its analogs block the interactions between Receptors for Advanced Glycation End-products (RAGE) and S100P [12].

Despite the growing evidence that S100 proteins are involved in the inflammation process of asthma it is still not clear which immunological pathways are followed and what are the relevant mechanisms. Although S100 proteins are considered pro-inflammatory, Hsu et al., have proven that corticosteroids (CSs) up-regulate S100 proteins in macrophages in vitro and in vivo [13]. Bozinovski S et al suggest an anti-inflammatory function of these proteins [14]. In line with this, Zhao et al. reports that murine S100A8 inhibits IgE-mediated MCs activation and the intranasal administration of S100 by reducing key cytokines affecting eosinophil migration and mucous production minimized murine's asthma symptoms [15].

S100 proteins and the RAGE signaling pathway

S 100 proteins exert their biological functions via surface RAGE and Toll-Like receptor 4 (TLR4) [16]. S100s bind to the extracellular region of RAGE and activate various signaling pathways including the downstream pathways of Mitogen-Activated Protein Kinase (MAPK), serine protein kinase (SK), extracellular signal regulated kinase (ERK) and Nuclear Factor-kappa B (NF-kB) [17]. Immunohistochemical studies show that RAGE is present in bronchial and vascular smooth muscles, as well as in alveolar macrophages. It is also expressed in numerous immune cells including neutrophils, monocytes/macrophages, lymphocytes and dendritic cells [18]. As the majority of components of the innate immune system, the encoding gene for RAGE is localized within the Major Histocompatibility (MHC) class III [19]. The ligation of RAGE by S100P leads to proinflammatory cytokines secretion and cell activation and proliferation. The physiological interaction between S100P and RAGE has been demonstrated by co-immunoprecipitation in different cell types, including embryonic fibroblast and endothelial cells [20]. Suppression of RAGE by different methods, such as dominant negative mutant of RAGE (DnRAGE), anti-RAGE antibody, and RAGE antagonist peptide, effectively inhibited S100 protein induced cell proliferation, indicate that S100 signals mainly through RAGE [21].

In conclusion, S100 has various effects at many different cells of the respiratory and immune systems. Subsequently, S 100 proteins seem to have a crucial role in the pathogenesis of asthma that needs to be further investigated.




Figure 1: Role of S100 proteins in the pathogenesis of asthma. S100 proteins are expressed in neutrophils and eosinophils. Activated neutrophils and/or eosinophils stimulate the release of S100 proteins, probably by extracellular traps formation. S 100 proteins exert their biological functions via surface RAGE and Toll-Like receptor 4 (TLR4). S 100 bind to the extracellular region of RAGE. Receptor-mediated uptake of S100 proteins into cells lead to the activation of many signaling cascades and cytokines production. S 100 proteins exert different effects on various cells: mast cells degranulation, activation of neutrophils, activation of eosinophils to secrete cytokines IL-5, promote Th0 cells differentiation into Th2, bronchial epithelial cells (BECs) in cytokines (IL 25, IL-33) Epithelium-derived S100 proteins and cytokines (IL-25, IL-33) provide a positive feedback to BECs and subsequently enhance production of mucous and matrix proteins. The above suggest that S100 proteins are involved in the innate defense mechanism of the bronchial epithelium.

References

1. Lemanske RF Jr, Busse WW (2006) Asthma: factors underlying inception, exacerbation, and disease progression. *J Allergy Clin Immunol* 117: S456–S461.
2. Saraya T, Kurai D, Ishii H, Ito A, Sasaki Y, et al. (2014) Epidemiology of virus-induced asthma exacerbations: with special reference to the role of human rhinovirus. *Front Microbiol* 5: 226.
3. Cassimos DC, Tsalkidis A, Tripsianis GA, Stogiannidou A, Anthracopoulos M, et al. (2008) Asthma, lung function and sensitization in school – children with a history of bronchiolitis. 50: 51–56.
4. Khalkhali HR, Oshnouei S, Salarilak S, Rahimi Rad M, Karamyar M, et al. (2014) Effects of antibiotic consumption on children 2-8 years of age developing asthma. *Epidemiol Health* 36: e2014006.
5. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, et al. (2003) Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. *Rheumatology (Oxford)* 42: 1383–1389.
6. Wu J, Kobayashi M, Sousa EA, Liu W, Cai J, et al. (2005) Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. *Mol Cell Proteomics* 4: 1251-1264.
7. Gioka T, Konstantinidis T, Tsigalou C, Hatzioannou E, Kampourimiti G, et al. (2014) PD46 - Serum level of S 100 proteins in patients with asthma. *Clin Transl Allergy* 4: P46.
8. Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan HR, et al. (2008) Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. *Respir Med* 102: 567–573.
9. Konstantinidis TG, Tsigalou C, Bisiklis A, Romanidou G, Konstantinidou E, et al. (2012) Autoantibodies In Patients With Asthma: Is There A Link Between Asthma And Autoimmunity? *Int J Immun Studies* 1: 376–387.
10. Poletaev A, Osipenko L (2003) General network of natural autoantibodies as immunological homunculus (Immunculus). *Autoimmun. Rev* 2: 264–271.
11. Camoretti-Mercado B, Karrar E, Nuñez L, Hofmann Bowman MA (2012) S100A12 and the Airway Smooth Muscle: Beyond Inflammation and Constriction. *J Aller Ther* S1:007.

12. Arumugam T, Ramachandran V, Logsdon CD (2006) Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. *J Natl Cancer Inst* 98: 1806–1818.
13. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, et al. (2005) Regulation of S100A8 by glucocorticoids. *J Immunol* 174: 2318–2326.
14. Bozinovski S, Cross M, Vlahos R, Jones JE, Hsuu K, et al. (2005) S100A8 chemotactic protein is abundantly increased, but only a minor contributor to LPS-induced, steroid resistant neutrophilic lung inflammation in vivo. *J Proteome Res* 4: 136–145.
15. Zhao J, Endoh I, Hsu K, Tedla N, Endoh Y, et al. (2011) S100A8 modulates mast cell function and suppresses eosinophil migration in acute asthma. *Antioxid Redox Signal* 14: 1589–1600.
16. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity and cancer. *J Leukoc Biol.* 86: 557–566.
17. Penumutthu SR, Chou RH, Yu C (2014) Structural Insights into Calcium-Bound S100P and the V Domain of the RAGE Complex. *PLoS ONE* 9: e103947.
18. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. *Am. J. Pathol* 143: 1699–1712.
19. Ott Ch, Jacobs K, Haucke E, Navarrete Santos A, Grune T, et al. (2014) Role of advanced glycation end products in cellular signaling. *Redox Biol* 2: 411–429.
20. Hsieh HL, Schafer BW, Weigle B, Heizmann CW (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. *Biochem Biophys Res Commun* 316: 949–959.
21. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD (2004) S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). *J Biol Chem* 279: 5059–5065.